Essex Investment Management’s Novartis NVS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $286K | Sell |
1,875
-900
| -32% | -$138K | 0.05% | 189 |
|
|
2025
Q4 | $383K | Hold |
2,775
| – | – | 0.06% | 179 |
|
|
2025
Q3 | $356K | Hold |
2,775
| – | – | 0.05% | 176 |
|
|
2025
Q2 | $336K | Hold |
2,775
| – | – | 0.06% | 172 |
|
|
2025
Q1 | $309K | Hold |
2,775
| – | – | 0.06% | 169 |
|
|
2024
Q4 | $270K | Hold |
2,775
| – | – | 0.05% | 175 |
|
|
2024
Q3 | $319K | Sell |
2,775
-850
| -23% | -$96.4K | 0.06% | 173 |
|
|
2024
Q2 | $386K | Hold |
3,625
| – | – | 0.07% | 170 |
|
|
2024
Q1 | $351K | Hold |
3,625
| – | – | 0.07% | 186 |
|
|
2023
Q4 | $366K | Hold |
3,625
| – | – | 0.07% | 192 |
|
|
2023
Q3 | $369K | Sell |
3,625
-228
| -6% | -$23.1K | 0.06% | 247 |
|
|
2023
Q2 | $389K | Sell |
3,853
-170
| -4% | -$17K | 0.05% | 262 |
|
|
2023
Q1 | $370K | Hold |
4,023
| – | – | 0.05% | 260 |
|
|
2022
Q4 | $365K | Sell |
4,023
-78
| -2% | -$6.57K | 0.06% | 258 |
|
|
2022
Q3 | $312K | Hold |
4,101
| – | – | 0.05% | 261 |
|
|
2022
Q2 | $347K | Hold |
4,101
| – | – | 0.06% | 262 |
|
|
2022
Q1 | $360K | Hold |
4,101
| – | – | 0.04% | 283 |
|
|
2021
Q4 | $359K | Hold |
4,101
| – | – | 0.04% | 286 |
|
|
2021
Q3 | $335K | Hold |
4,101
| – | – | 0.04% | 289 |
|
|
2021
Q2 | $374K | Sell |
4,101
-1,225
| -23% | -$109K | 0.04% | 301 |
|
|
2021
Q1 | $455K | Hold |
5,326
| – | – | 0.06% | 292 |
|
|
2020
Q4 | $503K | Sell |
5,326
-75
| -1% | -$6.55K | 0.06% | 288 |
|
|
2020
Q3 | $470K | Sell |
5,401
-149
| -3% | -$12.9K | 0.07% | 309 |
|
|
2020
Q2 | $485K | Hold |
5,550
| – | – | 0.08% | 261 |
|
|
2020
Q1 | $458K | Sell |
5,550
-1,408
| -20% | -$126K | 0.09% | 230 |
|
|
2019
Q4 | $659K | Hold |
6,958
| – | – | 0.08% | 289 |
|
|
2019
Q3 | $605K | Sell |
6,958
-2,156
| -24% | -$194K | 0.09% | 274 |
|
|
2019
Q2 | $832K | Sell |
9,114
-1,057
| -10% | -$89.5K | 0.11% | 251 |
|
|
2019
Q1 | $876K | Sell |
10,171
-7,201
| -41% | -$578K | 0.13% | 217 |
|
|
2018
Q4 | $1.34M | Buy |
17,372
+7,395
| +74% | +$576K | 0.21% | 148 |
|
|
2018
Q3 | $770K | Sell |
9,977
-143
| -1% | -$10.6K | 0.09% | 264 |
|
|
2018
Q2 | $685K | Hold |
10,120
| – | – | 0.09% | 269 |
|
|
2018
Q1 | $733K | Buy |
10,120
+66
| +0.7% | +$5.02K | 0.1% | 243 |
|
|
2017
Q4 | $756K | Hold |
10,054
| – | – | 0.1% | 239 |
|
|
2017
Q3 | $773K | Sell |
10,054
-446
| -4% | -$33.7K | 0.11% | 230 |
|
|
2017
Q2 | $785K | Hold |
10,500
| – | – | 0.11% | 223 |
|
|
2017
Q1 | $699K | Buy |
10,500
+87
| +0.8% | +$5.8K | 0.11% | 231 |
|
|
2016
Q4 | $680K | Hold |
10,413
| – | – | 0.11% | 215 |
|
|
2016
Q3 | $737K | Sell |
10,413
-58
| -0.6% | -$4.23K | 0.12% | 212 |
|
|
2016
Q2 | $774K | Hold |
10,471
| – | – | 0.13% | 185 |
|
|
2016
Q1 | $680K | Hold |
10,471
| – | – | 0.12% | 182 |
|
|
2015
Q4 | $807K | Hold |
10,471
| – | – | 0.13% | 175 |
|
|
2015
Q3 | $862K | Sell |
10,471
-10,146
| -49% | -$903K | 0.14% | 159 |
|
|
2015
Q2 | $1.82M | Sell |
20,617
-811
| -4% | -$74.4K | 0.27% | 94 |
|
|
2015
Q1 | $1.89M | Buy |
21,428
+10,957
| +105% | +$972K | 0.26% | 93 |
|
|
2014
Q4 | $869K | Hold |
10,471
| – | – | 0.13% | 172 |
|
|
2014
Q3 | $883K | Hold |
10,471
| – | – | 0.14% | 173 |
|
|
2014
Q2 | $849K | Hold |
10,471
| – | – | 0.13% | 202 |
|
|
2014
Q1 | $798K | Hold |
10,471
| – | – | 0.12% | 209 |
|
|
2013
Q4 | $754K | Buy |
10,471
+22
| +0.2% | +$1.53K | 0.11% | 228 |
|
|
2013
Q3 | $718K | Hold |
10,449
| – | – | 0.11% | 204 |
|
|
2013
Q2 | $662K | Buy |
+10,449
| New | +$680K | 0.12% | 198 |
|
Other funds holding NVS
Essex Investment Management's NVS Position: Q1 2026 in Review
Essex Investment Management reduced its Novartis (NVS) stake by 32% in Q1 2026, selling an estimated $138K and leaving 1,875 shares worth $286K. The position accounts for 0.05% of the portfolio, ranked #189.
Essex Investment Management first reported a position in NVS in Q2 2013 and has held it in 52 quarters since. The position peaked at $1.89M in Q1 2015. 1,598 funds tracked by Wall St. Rank hold NVS as of Q1 2026.
- Essex Investment Management held 1,875 shares of Novartis worth $286K as of Q1 2026.
- Essex Investment Management sold 900 Novartis shares in Q1 2026, an estimated $138K.
- Novartis made up 0.05% of Essex Investment Management's portfolio in Q1 2026, its #189 holding.
- Essex Investment Management first reported a position in Novartis in Q2 2013 and has held it in 52 quarters since.
- Essex Investment Management's Novartis position peaked at $1.89M in Q1 2015.
- 1,598 funds tracked by Wall St. Rank held Novartis as of Q1 2026.
Based on Essex Investment Management's 13F filing for Q1 2026, filed 11 May 2026.